Literature DB >> 910465

The disposition and metabolism of 3',4',7-tri-O-(beta-hydroxyethyl)rutoside and 7-mono-O-(beta-hydroxyethyl)rutoside in the mouse.

A M Hackett, L A Griffiths.   

Abstract

1. Following intravenous administration of 3',4',7-tri-O-(beta-hydroxy[14C2]ethyl)rutoside or 7-mono-O-(beta-hydroxy[14C2]ethyl)rutoside to male mice, 68% of the dose of each is excreted in faeces as the corresponding hydroxyethyl-quercetin within 72 h of dosage. Mean urinary excretions of mono- and tri-hydroxyethylrutosides in 72 h were 27 and 21% respectively. Unchanged rutosides and their glucuronides were detected in urine. 2. In biliary-cannulated animals, the mean biliary excretion of both tri- and mono-hydroxyethylrutosides was 71%, in 24 h of dosage. In both cases most 14C was excreted in 3 h, as unchanged rutosides and glucuronide conjugates. 3. Fall of blood 14C concn, was rapid for both compounds. Neither compound was detected in brain but there was short-term accumulation in liver and kidney, and 2--3 h after dosage, most 14C for both compounds was associated with the gastro-intestinal contents. 4. Animals killed 72 h after dosage of either compound contained less than 7% of dose, mostly in the colon and caecal contents. 5. Foetuses removed 3 h after dosage of either compound to the dams did not contain 14C; foetuses removed 5 min after dosage contained low levels of 14C, substantially below the maternal blood level and equiv. to less than 0-1% of dose in each case. No 14C was detected in amniotic fluid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 910465     DOI: 10.3109/00498257709038686

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  3 in total

1.  The metabolism and excretion of 7-mono-0-(beta-hydroxyethyl) rutoside in the dog.

Authors:  A M Hackett; L A Griffiths
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

2.  Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

Authors:  S A van Acker; K Kramer; J A Grimbergen; D J van den Berg; W J van der Vijgh; A Bast
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

3.  The disposition of 3-O-methyl-(+)-catechin in the rat and the marmoset following oral administration.

Authors:  A M Hackett; L A Griffiths
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.